$ME News
Last published 1y ago
- 1y agoME23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable LawGlobeNewswireSAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from
- 1y agoME23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversightCNBC23andMe co-founder Linda Avey expressed frustration about the fall of the genetic testing company in a social media post.
- 1y agoMEWith 23andMe entering bankruptcy, here's how to delete your genetic dataCNBCNow that 23andMe has filed for bankruptcy, another company could take control of its genetic database.
- 1y agoME23andMe files for bankruptcy, Anne Wojcicki steps down as CEOCNBCAnne Wojcicki has resigned from her role as chief executive effective immediately, though she will remain a member of the board.
- 1y agoME23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale ProcessGlobeNewswireIntends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for
- 1y agoME23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab TestGlobeNewswireSAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a
- 1y agoME23andMe special committee again rejects CEO Wojcicki's take-private offerCNBC23andMe's special committee of independent directors on Monday rejected CEO Anne Wojcicki's proposal to take the distressed genetic testing company private.
- 1y agoME23andMe Special Committee Rejects Acquisition Proposal From CEO Anne WojcickiGlobeNewswireSUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME) today confirmed receipt of a non-binding proposal
- 1y agoMEAnne Wojcicki has a new offer to take 23andMe private, this time for $74.7 millionCNBC23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private.
- 1y agoME23andMe Launches New Genetic Report on OsteoporosisGlobeNewswireSUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released
- 1y agoME23andMe is exploring strategic alternatives, looking to raise capitalCNBC23andMe said it's started exploring strategic alternatives, including a possible sale.
- 1y agoME23andMe Special Committee Announces Exploration of Strategic AlternativesGlobeNewswireSUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (NASDAQ:ME) ("23andMe" or the "Company"), a leading human genetics company with a mission to
- 1y agoME23andMe Reports Third Quarter Fiscal Year 2025 Financial ResultsGlobeNewswireCompany Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co.
- 1y agoME23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted TechnologyGlobeNewswireSUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling
- 1y agoHIMSPGNYTDOCGDRX+6Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdownCNBCIt's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.
- 1y agoME23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & InflammationGlobeNewswireSUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine
- 1y agoME23andMe Holding Co. (ME) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoME23andMe reports sales decline a day after announcing plans to cut 40% of workforceCNBCEmbattled genetic testing provider 23andMe said Tuesday that revenue declined from a year earlier, a day after the company announced a cost-cutting plan.
- 1y agoME23andMe Reports Second Quarter Fiscal Year 2025 Financial ResultsGlobeNewswireSUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025
- 2y agoME23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the FutureGlobeNewswireReduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic
- 2y agoMECORRECTION - 23andMe to Report Q2 FY2025 Financial ResultsGlobeNewswireSUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal
- 2y agoME23andMe to Report Q2 FY2025 Financial ResultsGlobeNewswireSUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the
- 2y agoME23andMe Regains Compliance With Nasdaq Listing RequirementsGlobeNewswireSUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced that the Company has regained
- 2y agoME23andMe appoints three new board members following abrupt resignationsCNBC23andMe appointed three new independent directors to its board, the company said Tuesday.
- 2y agoANSSCDLXLSCCME+123andMe Appoints Three New Independent Directors to BoardGlobeNewswireSUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre
- 2y agoMEInside the fall of 23andMeCNBCOnce worth $6 billion, 23andMe has lost 98% of its value and is on the verge of being delisted from the Nasdaq. So what happened?
- 2y agoME23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the SouthGlobeNewswireSUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company, released a powerful new feature that enables African American customers to trace their roots to
- 2y agoME23andMe Announces Completion of 1-for-20 Reverse Stock SplitGlobeNewswireSUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), announced today the completion of the previously announced 1-for-20 reverse stock split of the
- 2y agoME23andMe Announces 1-for-20 Reverse Stock SplitGlobeNewswireSUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), announced today that the 1-for-20 reverse stock split of the Company's Class A and Class B common stock
- 2y agoME23andMe Announces Mathew Knowles as New Brand AmbassadorGlobeNewswireSUNNYVALE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (NASDAQ:ME), a leading human genetics and preventive health company, today announced an ongoing collaboration with Mathew Knowles, father of
- 2y agoME23andMe Launches New Genetic Report on Likelihood of Frequent Emotional EatingGlobeNewswireSUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (NASDAQ:ME), a leading human genetics and preventive health company, today released a new report on the genetics of emotional eating for
- 2y agoMEBarrack, Rodos & Bacine Is Investigating 23andMe Holding Co.GlobeNewswirePHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine is investigating 23andMe Holding Co. (NASDAQ:ME) regarding the mass resignation of all of the independent members of the
- 2y agoMEWolf Popper LLP is Investigating Whether the Offer to Acquire 23andMe Holding Co. By Its Controlling Shareholder Is Fair to the Minority ShareholdersGlobeNewswireNEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating claims on behalf of investors in 23andMe Holding Co. (NASDAQ:ME) concerning the offer to acquire 23andMe by its controlling shareholder,
- 2y agoME23andMe CEO Anne Wojcicki 'surprised and disappointed' by board resignations: Read the memoCNBCIn a memo to employees on Tuesday, 23andMe CEO Anne Wojcicki said the company will search for new directors.
- 2y agoMEIndependent Directors of 23andMe Resign from BoardGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (NASDAQ:ME), today sent the following letter to Anne Wojcicki, Chief Executive Officer,
- 2y agoME23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 StudyGlobeNewswire23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with
- 2y agoME23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 TrialGlobeNewswire23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of
- 2y agoMEOne of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All PopulationsGlobeNewswireSUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at National Human Genome
- 2y agoME23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024GlobeNewswirePreliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with 23ME-00610 efficacy to
- 2y agoMELemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership ProgramGlobeNewswireSUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (NASDAQ:ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and
- 2y agoME23andMe Holding Co. (ME) Q1 2025 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoME23andMe Reports First Quarter Fiscal 2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal
- 2y agoME23andMe Special Committee responds to CEO's take-private proposalGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today sent the
- 2y agoME23andMe Announces CEO's Take-Private ProposalGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, has received a preliminary non-binding indication of interest from
- 2y agoME23andMe CEO Anne Wojcicki files proposal to take company private as stock cratersCNBC23andMe CEO Anne Wojcicki has submitted a proposal to take the genetic testing company private.
- 2y agoME23andMe to Report Q1 FY2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and
- 2y agoMETwenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance ResearchGlobeNewswireSUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced
- 2y agoME23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker PanelGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk
- 2y agoME23andMe Launches New Genetic Report on Bipolar DisorderGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by
- 2y agoME23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black CommunityGlobeNewswireSUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest